Meeting
2020 ASCO Virtual Scientific Program
Tumor mutational load, microsatellite instability and actionable mutations in metastatic colorectal cancer: Results from the TRIBE2 study.
Authors
Carlotta Antoniotti
Department of Translational Research and New Technologies in Medicine and Surgery, Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy
Carlotta Antoniotti , Federica Marmorino , Sara Lonardi , Francesca Corti , Daniele Rossini , Roberto Moretto , Clara Ugolini , Mirella Giordano , Emiliano Tamburini , Daniele Santini , Giuseppe Aprile , Roberto Bordonaro , Gemma Zucchelli , Gabriella Fontanini , Heinz-Josef Lenz , Alfredo Falcone , Wolfgang Michael Korn , Chiara Cremolini
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Epidemiology/Outcomes
Citation
J Clin Oncol 38: 2020 (suppl; abstr 4077)
DOI
10.1200/JCO.2020.38.15_suppl.4077
Abstract #
4077
Poster Bd #
69
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Somatic DNA mutations, tumor mutational burden (TMB), and MSI Status: Association with efficacy in patients (pts) with metastatic colorectal cancer (mCRC) of FIRE-3 (AIO KRK-0306).
First Author: Volker Heinemann
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Tissue factor: A link between metastatic colorectal cancer and thrombosis in patients in the CALGB (Alliance)/SWOG 80405 trial.
First Author: Sandra Algaze
First Author: Sandra Algaze
Poster
2019 ASCO Annual Meeting
BRCA1 genetic variant to predict survival in metastatic colorectal cancer (mCRC) patients (pts) treated with FOLFIRI/bevacizumab (bev): Results from phase III TRIBE and FIRE-3 trials.
First Author: Madiha Naseem